RVMD

Shares of Tango Therapeutics TNGX surged 53% on Monday after the company reported encouraging initial data from an ongoing phase I/II study evaluating combination treatments involving its investigational drug, vopimetostat. The study is assessing vopimetostat plus one of Revolution Medicines’ RVMD experimental RAS inhibitors — daraxonrasib or zoldonrasib — in previously treated patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The strongest results were reported from the vopimetostat-daraxonrasib arm. Among 12 evaluable patients, the combination achieved an objective response rate (ORR) of 92%, with a disease control rate (DCR) of 100% and a six-month progression-free survival (PFS) rate of 90%. In contrast, the vopimetostat-zoldonrasib combination achieved a 52% ORR across 27 evaluable patients, a DCR of 96% and a six-month PFS rate of 74%. Both combinations were generally well tolerated. The data drew significant attention from investors and analysts, many of whom were particularly impressed by the vopimetostat-daraxonrasib results. Investors also welcomed the company's decision to advance this combination into late-stage development for first-line MTAP-deleted pancreatic cancer. Management believes the findings support the broader strategy of combining PRMT5 inhibition with RAS-targeted therapies and reinforce the potential for a chemotherapy-free treatment option in patients with MTAP-deleted pancreatic cancer. Year to date, the company’s shares have skyrocketed 249% against the industry’s 3% fall. Image Source: Zacks Investment Research The drug is a selective PRMT5 inhibitor designed to target cancers harboring MTAP deletions, a genetic alteration found across multiple tumor types, including pancreatic cancer. Apart from the above study, vopimetostat is also being tested as a monotherapy in a phase I/II study across MTAP-deleted solid tumors. Data from this study is expected later this year. In March, Tango Therapeutics entered into a clinical trial collaboration and supply agreement with Erasca ERAS. Under the agreement, the companies will evaluate vopimetostat in combination with ERAS' pan-RAS molecular glue, ERAS-0015, in patients with MTAP-deleted RAS-mutant cancers. Tango plans to initiate a phase I/II study before year-end, further expanding the development opportunities for vopimetostat. Tango Therapeu...

Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines' results in pancreatic cancer.

Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat,

A month has gone by since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 9.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Revolution Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers. Revolution Medicines reported a first-quarter 2026 loss of $2.29 per share, wider than the Zacks Consensus Estimate of a loss of $1.83. The company had incurred a loss of $1.13 in the year-ago quarter. Currently, the company does not have any approved products in its portfolio. It has yet to generate revenues. Research and development expenses amounted to about $344 million, up 67% year over year. This significant increase was primarily driven by higher costs associated with clinical studies and manufacturing for the company’s drug candidates. General and administrative expenses surged 189% to $101.3 million, primarily driven by higher stock-based compensation expenses, headcount costs and administrative costs, as well as increased commercial preparation activities during the quarter. The company revised its guidance for operating expenses. It expects the figure to be between $1.7 billion and $1.8 billion (previously: $1.6-$1.7 billion), which includes non-cash stock-based compensation expense of $260-$280 million (previously: $180-$200 million). In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -8.19% due to these changes. At this time, Revolution Medicines has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock has a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Revolution Medicines has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Revolution Medicines is part of the Zacks Medical - Biome...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Revolution Medicines (RVMD) is back in focus after presenting detailed Phase 3 results for its RASolute 302 trial at ASCO 2026, where oral RAS(ON) inhibitor daraxonrasib doubled median overall survival versus chemotherapy. See our latest analysis for Revolution Medicines. The latest daraxonrasib data has come alongside powerful momentum in the stock, with a 90 day share price return of 58.22% and a year to date share price return of 97.03%. The 1 year total shareholder return of 287.29% and very large 3 year total shareholder return suggest investors have been steadily repricing Revolution Medicines as clinical and regulatory milestones accumulate. If the RASolute 302 results have you thinking about where else breakthrough treatments could emerge next, it may be worth scanning for other oncology and biotech ideas through our 40 healthcare AI stocks With Revolution Medicines now worth about US$33.2b and the stock up very sharply over the past year, the key question is whether current prices still leave room for upside or if the market is already factoring in several years of future growth. At a last close of $155.69 versus a most followed fair value estimate of $133.70, the current price sits above what that narrative implies. Read the complete narrative. Curious what kind of revenue curve and margin profile that outlook assumes, and what sort of future earnings multiple ties it all together. Result: Fair Value of $133.70 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, heavy 2026 operating expenses of US$1.6b to US$1.7b and the company’s reliance on a concentrated RAS oncology pipeline could quickly test that optimistic setup. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. While the most followed narrative pegs fair value at $133.70 and flags the stock as overvalued, our DCF model lands in a very different place, with an estimate of $611.60 per share that frames RVMD as deeply undervalued. When two approaches disagree this shar...

Shares of Revolution Medicines RVMD were rising in pre-market today after the company reported full results from the phase III RASolute 302 study, which evaluated lead candidate daraxonrasib in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). These findings were also presented at the 2026 ASCO Annual Meeting yesterday and simultaneously published in the New England Journal of Medicine. Though Revolution Medicines previously reported in April that the study met all primary and secondary endpoints based on interim analysis, the latest findings provide a more comprehensive look at the drug’s clinical benefit. The study enrolled a broad patient population, including those with diverse RAS mutations, particularly G12 variants, as well as those without identifiable RAS mutations. Participants were randomized to receive either 300 mg of oral daraxonrasib once daily or standard-of-care cytotoxic chemotherapy delivered intravenously. The primary endpoints included overall survival (OS) and progression-free survival (PFS) in patients with RAS G12-mutant tumors, while key secondary endpoints assessed these outcomes in the overall study population. Across the RAS G12 population, daraxonrasib reduced the risk of death by 60% compared with standard chemotherapy and achieved a median OS of 13.2 months compared to 6.6 months for chemotherapy. The drug also demonstrated a significant benefit on PFS, with median PFS improving to 7.3 months from 3.5 months with chemotherapy. Similar benefits were seen across the overall study population. Daraxonrasib reduced the risk of death by 60% and improved median OS to 13.2 months compared with 6.7 months for chemotherapy. Median PFS stood at 7.2 months for daraxonrasib versus 3.6 months with chemotherapy. The drug was generally well-tolerated and demonstrated a manageable safety profile. Management noted that patients receiving daraxonrasib experienced meaningful improvements in patient-reported outcomes, including significant delays in the deterioration of cancer-related pain, overall global health status and quality of life. Per Revolution Medicines, these findings strengthen daraxonrasib's potential to become a new treatment option for previously treated metastatic PDAC, a setting where effective therapies remain limited. Based on the above data, the company intends to advance regulatory submission...

Results simultaneously published in The New England Journal of Medicine REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results will be presented during a late-breaking Plenary Session (LBA5) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting at 3:21 p.m. CDT today and were published today in The New England Journal of Medicine. RAS, a key growth control switch in human cells, is the primary oncogenic driver of PDAC, a disease that is typically characterized by excessive RAS(ON) signaling in tumors with or without a mutant allele of RAS. Daraxonrasib is the first investigational agent in a novel class of RAS(ON) multi-selective inhibitors designed to address a diverse and broad spectrum of RAS variants. In the randomized Phase 3 RASolute 302 trial, once-daily oral daraxonrasib demonstrated unprecedented improvements in overall survival (OS) and progression-free survival (PFS) compared to standard of care cytotoxic chemotherapy in patients with previously treated metastatic PDAC, with or without an identified tumor RAS mutation. All primary and key secondary endpoints of the trial were met. Daraxonrasib exhibited a manageable safety profile and patients treated with daraxonrasib reported significantly delayed deterioration in cancer-related pain, overall global health status and quality of life, compared to those treated with chemotherapy. “Revolution Medicines has been singularly focused on developing bold new targeted medicines for treating patients with RAS-driven cancers, which are some of the most aggressive and difficult-to-treat diseases in oncology. The data from the Phase 3 RASolute 302 trial clearly validate our pioneering, science-driven approach and add to the growing body of evidence underscoring the broad potential of RAS(ON) inhibition that we are testing across pancreatic cancer and other RAS-driven cancers,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “Daraxon...

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines’ senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn. Revolution Medicines Media & Investor Contact:[email protected]@revmed.com

Image source: The Motley Fool. Wednesday, May 6, 2026 at 4:30 p.m. ET Chairman and Chief Executive Officer — Mark Goldsmith Chief Development Officer — Alan Bart Sandler Chief Financial Officer — Jack Anders President of R&D — Stephen Kelsey Chief Medical Officer — Wei Lin Chief Global Commercialization Officer — Anthony Mancini Need a quote from a Motley Fool analyst? Email [email protected] Mark Goldsmith, Revolution Medicines, Inc. Chairman and Chief Executive Officer; Alan Bart Sandler, our Chief Development Officer; and Jack Anders, our Chief Financial Officer. Stephen Kelsey, our President of R&D; Wei Lin, our Chief Medical Officer; and Anthony Mancini, our Chief Global Commercialization Officer, will join us for the Q&A portion of today’s call. We would like to inform you that certain statements we make during this call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in forward-looking statements. For a full discussion of these risks and uncertainties, please review our Annual Report on Form 10-Ks and our Quarterly Report on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended March 31, 2026 and recent corporate updates. The press release and updated corporate presentation are available on the Investors section of our website at revmed.com. With that, I will turn the call over to Mark Goldsmith, Revolution Medicines, Inc. Chairman and Chief Executive Officer. Mark? Mark Goldsmith: Thanks, Ryan. It is good to be with you this afternoon to discuss the tremendous progress we have made in 2026. This is a pivotal moment for our organization and for patients worldwide living with pancreatic cancer who are in need of new therapeutic options. It is anchored by the top-line readout for RESOLUTE-302 last month, in which diraxonrasib monotherapy demonstrated an unprecedented improvement in overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer. The RESOLUTE-302 results represent a transformative advance for patients. They also firmly validate our pioneering RAS(ON) inhibitor strategy and reinforce its potential to improve outcomes in RAS-driven cancers. High investor conviction enabled a historic 2 billion...

Revolution Medicines (RVMD) reported Wednesday fiscal Q1 net loss of $2.29 per diluted share, wideni

Royalty Pharma reported a “strong start” to 2026 with 10% growth in portfolio receipts and 13% growth in royalty receipts, deployed more than $0.5 billion of capital (with $1.25 billion announced), repurchased 1 million shares for $50 million, raised the dividend 7%, and raised full‑year 2026 guidance to $3.325–$3.45 billion. The company struck material deals and saw major portfolio catalysts, including a $250 million funding for Zymeworks’ Ziihera royalty (peak sales modeled >$2 billion) and a $500 million synthetic royalty investment in Revolution Medicines’ daraxonrasib after trial data showed a near doubling of overall survival, driving expectations for substantial peak royalties. Balance-sheet strength and strategic positioning underpin growth: cash of $586 million, investment‑grade debt of $9.2 billion with leverage ~2.9x and an undrawn $1.8 billion revolver (Fitch upgrade to BBB), while the firm is expanding into R&D co‑funding (first‑quarter deals with J&J and Teva ~ $1 billion) to capture a large biopharma R&D opportunity. Interested in Royalty Pharma PLC? Here are five stocks we like better. How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma (NASDAQ:RPRX) reported what executives described as a “strong start” to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management’s remarks on the company’s first-quarter earnings call. Chief Executive Officer and Chairman Pablo Legorreta said the company delivered “10% growth in portfolio receipts” and “13% growth in royalty receipts,” which he characterized as Royalty Pharma’s recurring cash flows. Legorreta added that performance was supported by the “strength of our diversified portfolio,” and said the company maintained “returns on invested capital of around 14% and returns on invested equity of around 20%.” → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries 1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data Legorreta also highlighted capital deployment during the quarter, citing “$1.25 billion of announced transactions on three attractive therapies,” with capital deployed “in excess of $0.5 billion dollars.” He said Royalty Pharma repurchased 1 million shares for $50 million and increased its dividend by 7% during the quarter. C...

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration AACR 2026 presentations reinforce the breadth and strength of company’s RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition Strengthened financial position with financings totaling $2.2 billion in gross proceeds Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress. “Last month we reported positive results from the RASolute 302 trial of daraxonrasib, demonstrating an unprecedented improvement in overall survival in patients with previously treated metastatic pancreatic cancer,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “These results, which we intend to submit to global health authorities, mark a major advance for patients and strengthen our conviction in our RAS(ON) inhibition strategy across RAS-driven cancers. Reinforced by a growing body of evidence supporting our portfolio led by four innovative clinical-stage RAS(ON) inhibitors and continued expansion of our commercialization capabilities, our goal is to build Revolution Medicines into a leading targeted oncology company capable of delivering impactful therapies to patients worldwide.” Clinical Highlights Pancreatic Ductal Adenocarcinoma (PDAC) Daraxonrasib in PDAC Daraxonrasib, a pioneering oral RAS(ON) multi-selective inhibitor, continues to demonstrate a differentiated clinical profile across lines of therapy and in both monotherapy and combination settings. The company recently announced positive topline results from the pivotal, randomized Phase 3 RASolute 302 trial in second line (2L) PDAC, marking a major milestone in the development of daraxonrasib by showing its potential to improve patient outcomes. Daraxonrasib demonstrated stati...